[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609637":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":58,"centralContacts":62,"locations":68,"responsibleParty":219,"collaborators":54,"id":221,"slug":222,"hasResults":223,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":54,"eligibilityCriteria":227,"healthyVolunteers":223,"sex":228,"minAge":229,"maxAge":54,"enrollmentInfo":230,"targetDuration":54,"studyType":233,"phases":234,"briefSummary":236,"conditions":237,"keywords":249,"overallStatus":71,"whyStopped":54,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":268},{"fullName":5,"class":6},"EvolveImmune United, Inc","INDUSTRY",[8,14,17,20,23,26,29,32,35,38,41,45],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a Cohort 1; dose level 1","EXPERIMENTAL","Active Study Drug",[13],"Drug: EVOLVE104",{"label":15,"type":10,"description":11,"interventionNames":16},"Phase 1a Cohort 2; dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Phase 1a Cohort 3; dose level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Phase 1a Cohort 4; dose level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Phase 1a Cohort 5; dose level 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Phase 1a Cohort 6; dose level 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Phase 1a Cohort 7; dose level 7",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"Phase 1a Cohort 8; dose level 8",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"Phase 1a Cohort 9; dose level 9",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"Phase 1a Cohort 10; dose level 10",[13],{"label":42,"type":10,"description":43,"interventionNames":44},"Phase 1b Cohort 1; dose level TBD","Active study drug",[13],{"label":46,"type":10,"description":43,"interventionNames":47},"Phase 1b Cohort 2; dose level TBD",[13],[49,55],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"DRUG","EVOLVE104","EVOLVE104 is provided as a solution for injection via IV infusion",[39,9,15,18,21,24,27,30,33,36],null,{"type":50,"name":51,"description":56,"armGroupLabels":57,"otherNames":54},"Dose levels for Phase 1b will be determined based on the outcome of Phase 1a",[42,46],[59],{"name":60,"affiliation":5,"role":61},"EvolveImmune Study Team","STUDY_DIRECTOR",[63],{"name":64,"role":65,"phone":66,"phoneExt":54,"email":67},"Evolve Study Team","CONTACT","12032086584","Evolve104Study@evolveimmune.com",[69,86,98,111,124,137,149,158,167,180,193,206],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-117.97729,34.13945,{"lat":81,"lon":80},[84],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":85},"edwang@coh.org",{"facility":87,"status":71,"city":88,"state":73,"zip":89,"country":75,"countryCode":76,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"USC\u002FNorris Comprehensive Cancer Center","Los Angeles","90033",{"type":78,"coordinates":91},[92,93],-118.24368,34.05223,{"lat":93,"lon":92},[96],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":97},"Stephanie.kim2@med.usc.edu",{"facility":99,"status":71,"city":100,"state":101,"zip":102,"country":75,"countryCode":76,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Yale University Cancer Center","New Haven","Connecticut","06511",{"type":78,"coordinates":104},[105,106],-72.92816,41.30815,{"lat":106,"lon":105},[109],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":110},"alicia.appiah-chin@yale.edu",{"facility":112,"status":71,"city":113,"state":114,"zip":115,"country":75,"countryCode":76,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"The Winship Cancer Institute Emory University","Atlanta","Georgia","30322",{"type":78,"coordinates":117},[118,119],-84.38798,33.749,{"lat":119,"lon":118},[122],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":123},"alejandra.maria.bono@emory.edu",{"facility":125,"status":71,"city":126,"state":127,"zip":128,"country":75,"countryCode":76,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"START Midwest","Grand Rapids","Michigan","49546",{"type":78,"coordinates":130},[131,132],-85.66809,42.96336,{"lat":132,"lon":131},[135],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":136},"colleen.armstrong@startresearch.com",{"facility":138,"status":71,"city":139,"state":139,"zip":140,"country":75,"countryCode":76,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Icahn School of Medicine at Mount Sinai","New York","10029",{"type":78,"coordinates":142},[143,144],-74.00597,40.71427,{"lat":144,"lon":143},[147],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":148},"joseph.watters@mssm.edu",{"facility":150,"status":71,"city":139,"state":139,"zip":151,"country":75,"countryCode":76,"cosmosGeoPoint":152,"geoPoint":154,"contacts":155},"Columbia University Irving Medical Center","10032",{"type":78,"coordinates":153},[143,144],{"lat":144,"lon":143},[156],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":157},"jk4704@cumc.columbia.edu",{"facility":159,"status":71,"city":139,"state":139,"zip":160,"country":75,"countryCode":76,"cosmosGeoPoint":161,"geoPoint":163,"contacts":164},"Memorial Sloan Kettering Cancer Center","10065",{"type":78,"coordinates":162},[143,144],{"lat":144,"lon":143},[165],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":166},"iyerg@mskcc.org",{"facility":168,"status":71,"city":169,"state":170,"zip":171,"country":75,"countryCode":76,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Thomas Jefferson University, Sidney Kimmel Cancer Center","Philadelphia","Pennsylvania","19107",{"type":78,"coordinates":173},[174,175],-75.16362,39.95238,{"lat":175,"lon":174},[178],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":179},"Adjoa.Ntoso@jefferson.edu",{"facility":181,"status":71,"city":182,"state":183,"zip":184,"country":75,"countryCode":76,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"SCRI","Nashville","Tennessee","37203",{"type":78,"coordinates":186},[187,188],-86.78444,36.16589,{"lat":188,"lon":187},[191],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":192},"Meghan.McGuire@scri.com",{"facility":194,"status":71,"city":195,"state":196,"zip":197,"country":75,"countryCode":76,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":78,"coordinates":199},[200,201],-95.36327,29.76328,{"lat":201,"lon":200},[204],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":205},"GIclinicaltrials@mdanderson.org",{"facility":207,"status":71,"city":208,"state":209,"zip":210,"country":75,"countryCode":76,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":78,"coordinates":212},[213,214],-77.30637,38.84622,{"lat":214,"lon":213},[217],{"name":54,"role":65,"phone":54,"phoneExt":54,"email":218},"skamal@nextoncology.com",{"type":220,"investigatorFullName":54,"investigatorTitle":54,"investigatorAffiliation":54,"oldNameTitle":54,"oldOrganization":54},"SPONSOR","100609637","phase-1-a-study-evaluating-the-safety-efficacy-and-pharmacokinetics-pk-of-evolve104-in-participants-with-advanced-urothelial-and-squamous-cell-carcinomas-100609637",false,"NCT07217171","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas","Key Inclusion Criteria:\n\nParticipants must have locally advanced or metastatic cancer with one of the following tumor types: bladder cancer, squamous cell carcinoma of the lung, esophagus, skin, or an anogenital squamous cell carcinoma.\n\n1. Participant must have documented disease progression during or post treatment with standard of care, dependent upon tumor type.\n2. The cancer must be measurable by CT scan or MRI.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤1.\n4. Anticipated life expectancy of at least 3 months.\n5. Adequate organ function, as indicated by standard blood tests.\n6. Able to provide a fresh or archival tumor biopsy.\n7. Male and female participants must agree to use contraception during the study and for 120 days after the last dose of study drug, except for women who are post-menopausal or surgically sterile.\n\nKey Exclusion Criteria:\n\n1. The participant is a candidate for treatment with a targeted agent known to provide a benefit.\n2. Persistent significant toxicities from prior anticancer therapy.\n3. Brain metastases unless previously treated and stable.\n4. Prior severe or life-threatening immunologic reactions to previous therapies.\n5. Significant medical conditions, including but not limited to:\n\n   * History of clinically significant cardiac disease\n   * Severe esophageal disease such as esophageal rupture or severe erosive esophagitis.\n   * Active inflammatory corneal or conjunctival inflammation, erosion, or ulcerations.\n   * History of cirrhosis or significant portal hypertension.\n   * Uncontrolled or significant infection.\n   * History of certain other cancers in the past 3 years.\n   * History of arterial thrombosis, stroke and transient ischemic attack within 6 months.\n   * Active or uncontrolled HIV, HBV or HCV infection.\n   * Autoimmune or other condition requiring chronic systemic immunosuppression.","ALL","18 Years",{"count":231,"type":232},160,"ESTIMATED","INTERVENTIONAL",[235],"PHASE1","The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.",[238,239,240,241,242,243,244,245,246,247,248],"Bladder Cancer","Squamous Cell Carcinoma of the Lung","Esophageal Squamous Cell Carcinoma","Tongue Squamous Cell Carcinoma","Cutaneous Squamous Cell Cancer","Penile Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","Vulvar Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Vaginal Squamous Cell Carcinoma","Urethral Squamous Cell Carcinoma",[250,251,252,253,254,255,256,257,258],"bladder","lung","esophagus","tongue","penile","anal","vulvar","cervical","vaginal","2026-07-01",{"date":261,"type":262},"2026-07-02","ACTUAL",{"date":264,"type":262},"2025-11-13",{"date":266,"type":232},"2031-01-29",{"name":5,"class":6},12]